Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021
By LabMedica International staff writers Posted on 16 Nov 2021 |
Molbio Diagnostics (Goa, India) exhibited its novel POC Truelab molecular platform and Truenat range of tests at MEDICA 2021, the leading international trade fair for the medical sector.
Molbio presented its fully automatic Truelab real time quantitative micro PCR system with a sample to results time of less than one hour. Among the Truelab systems presented at the event was the fully automatic Truelab Uno Dx real time quantitative micro PCR analyzer with a three wavelength system that performs 10-12 tests in eight hours. Molbio also highlighted the fully automatic Truelab Duo real time quantitative micro PCR analyzer with a two channel-three wavelength system that performs 20-24 tests in eight hours, alongside the fully automatic Truelab Quattro real time quantitative micro PCR analyzer with four channel-three wavelength system that performs 40-48 tests in eight hours. Molbio's Truelab also fits in a suitcase that can be transported easily anywhere and used by anyone. The platform can test over 30 diseases with a sample-to-result time of less than an hour, and the results can be transmitted instantly to any place via the IoT enabled platform.
Additionally, Molbio presented its Truenat range of disease-specific real time micro PCR tests at MEDICA 2021. The micro PCR chips are pre-loaded, ready-to-use and disposable. They are disease-specific and can be run on the Truelab Uno Dx/Duo/Quattro to get quantitative real-time PCR results. Among its wide range of Truenat real time micro PCR tests highlighted at the event was Truenat COVID-19, a chip-based RT PCR test for the semi quantitative detection of SARS CoV-2 RNA in human oropharyngeal and nasopharyngeal swab specimen. Molbio also showcased its WHO-endorsed Truenat MTB test for the quantitative detection and diagnosis of Mycobacterium tuberculosis (MTB) in human pulmonary and EPTB specimens that aids in the diagnosis of infection with MTB.
Related Links:
Molbio Diagnostics
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection